Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.

A composition is provided for promoting skeletal muscle oxidative muscle fiber generation. The composition comprises a Lycium barbarum water extract. The Lycium barbarum extract comprises polysaccharide, Lycium barbarum flavone, carotenoid, polyphenol, and Lycium barbarum pigment. The composition may further comprise one or more pharmaceutically acceptable excipients selected from such as a solvent, a co-solvent, an emulsifier, a preservative, a buffer, a protein powder, or a combination thereof. The composition may be used as medicine, functional product, or food supplement.

A composition is provided for promoting skeletal muscle oxidative muscle fiber generation. The composition comprises a Lycium barbarum water extract. The Lycium barbarum extract comprises polysaccharide, Lycium barbarum flavone, carotenoid, polyphenol, and Lycium barbarum pigment. The composition may further comprise one or more pharmaceutically acceptable excipients selected from such as a solvent, a co-solvent, an emulsifier, a preservative, a buffer, a protein powder, or a combination thereof. The composition may be used as medicine, functional product, or food supplement.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.

Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.

The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.

The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.